Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...
According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...
2dOpinion
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...
3d
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update
CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...
When systems are built for hundreds of millions of people, efficiency becomes mandatory, inclusion critical, and cost ...
The food biotechnology industry is expanding as nations adopt technology to address food scarcity, climate stress, and nutritional deficiencies. Innovations in synthetic biology, gene editing, ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
The human gut microbiome, traditionally linked to infectious diseases, is now recognized as a hub of non-pathogenic microorganisms that play pivotal roles in host communication and homeostasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback